Press release
Hypoxia Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Eli Lilly, Biogen, AesRx, Threshold Pharmaceuticals, GlaxoSmithKline, Roche, Reven Pharmaceuticals
"Hypoxia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypoxia Market.
The Hypoxia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Hypoxia Pipeline Report: https://www.delveinsight.com/report-store/hypoxia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Hypoxia treatment therapies with a considerable amount of success over the years.
• Hypoxia companies working in the treatment market are Keros Therapeutics, Inc., Crocetinate Diffusion Pharmaceuticals, Reven Pharmaceuticals, ReAlta Life Sciences, Inc., Partner Therapeutics, Inc., Teclison Ltd., Merck Sharp & Dohme, Eli Lilly and Company, Biogen, AesRx, LLC, Threshold Pharmaceuticals, GlaxoSmithKline, Roche, Global Blood Therapeutics, Akebia Therapeutics, and others, are developing therapies for the Hypoxia treatment
• Emerging Hypoxia therapies in the different phases of clinical trials are- RKER-012, Trans Sodium, Rejuveinix, RLS-0071, Sargramostim, Tirapazamine, Belzutifan, Tirzepatide, TMS-007, Aes-103, TH-302, GSK2256294, RO7070179, GBT440, AKB-6548, and others are expected to have a significant impact on the Hypoxia market in the coming years.
• In March 2021, A two-part, two-cohort, double-blind, randomised, placebo-controlled, multicenter Phase 1/2 study to assess the safety, tolerability, and efficacy of REJUVEINIX (RJX) in patients with COVID-19 was started by Reven Pharmaceuticals, Inc.
• In March 2021, A Phase III clinical research was started by GlaxoSmithKline PC and IQVIA Pty Ltd to examine the effectiveness and safety of GSK3511294 (Depemokimab) in treating adult and adolescent patients with severe, uncontrolled asthma
• In February 2021, In order to assess the pharmacokinetic (PK) characteristics of a single subcutaneous (SC) dosage of tezepelumab in asthmatic children aged 5 to 11 years, AstraZeneca PLC and Amgen Inc. started a Phase I clinical research.
Hypoxia Overview
Hypoxia is a condition where there is insufficient oxygen delivery to the tissues due to either insufficient blood flow or insufficient oxygen levels in the blood (hypoxemia). This prevents the tissues from being able to maintain adequate homeostasis.
Get a Free Sample PDF Report to know more about Hypoxia Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/hypoxia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Hypoxia Drugs Under Different Phases of Clinical Development Include:
• RKER-012: Keros Therapeutics, Inc.
• Trans Sodium: Crocetinate Diffusion Pharmaceuticals
• Rejuveinix: Reven Pharmaceuticals
• RLS-0071: ReAlta Life Sciences, Inc.
• Sargramostim: Partner Therapeutics, Inc.
• Tirapazamine: Teclison Ltd.
• Belzutifan: Merck Sharp & Dohme
• Tirzepatide: Eli Lilly and Company
• TMS-007: Biogen
• Aes-103: AesRx, LLC
• TH-302: Threshold Pharmaceuticals
• GSK2256294: GlaxoSmithKline
• RO7070179: Roche
• GBT440: Global Blood Therapeutics
• AKB-6548: Akebia Therapeutics
Hypoxia Pipeline Therapeutics Assessment
• Hypoxia Assessment by Product Type
• Hypoxia By Stage and Product Type
• Hypoxia Assessment by Route of Administration
• Hypoxia By Stage and Route of Administration
• Hypoxia Assessment by Molecule Type
• Hypoxia by Stage and Molecule Type
DelveInsight's Hypoxia Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Hypoxia product details are provided in the report. Download the Hypoxia pipeline report to learn more about the emerging Hypoxia therapies at:
https://www.delveinsight.com/sample-request/hypoxia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Hypoxia Therapeutics Market include:
Key companies developing therapies for Hypoxia are - Teclison, Merck, Eli Lilly, Reven Pharmaceuticals, Biogen, AesRx, Threshold Pharmaceuticals, GlaxoSmithKline, Roche, Global Blood Therapeutics, Akebia Therapeutics, and others.
Hypoxia Pipeline Analysis:
The Hypoxia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hypoxia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypoxia Treatment.
• Hypoxia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hypoxia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypoxia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Hypoxia drugs and therapies-
https://www.delveinsight.com/sample-request/hypoxia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Hypoxia Pipeline Market Drivers
• Increase in prevalence of Hypoxia, increase in the demand for disease specific novel treatment are some of the important factors that are fueling the Hypoxia Market.
Hypoxia Pipeline Market Barriers
• However, lack of awareness about the disease, cost associated with the research and development and other factors are creating obstacles in the Hypoxia Market growth.
Scope of Hypoxia Pipeline Drug Insight
• Coverage: Global
• Key Hypoxia Companies: Keros Therapeutics, Inc., Crocetinate Diffusion Pharmaceuticals, Reven Pharmaceuticals, ReAlta Life Sciences, Inc., Partner Therapeutics, Inc., Teclison Ltd., Merck Sharp & Dohme, Eli Lilly and Company, Biogen, AesRx, LLC, Threshold Pharmaceuticals, GlaxoSmithKline, Roche, Global Blood Therapeutics, Akebia Therapeutics, and others
• Key Hypoxia Therapies: RKER-012, Trans Sodium, Rejuveinix, RLS-0071, Sargramostim, Tirapazamine, Belzutifan, Tirzepatide, TMS-007, Aes-103, TH-302, GSK2256294, RO7070179, GBT440, AKB-6548, and others
• Hypoxia Therapeutic Assessment: Hypoxia current marketed and Hypoxia emerging therapies
• Hypoxia Market Dynamics: Hypoxia market drivers and Hypoxia market barriers
Request for Sample PDF Report for Hypoxia Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/hypoxia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Hypoxia Report Introduction
2. Hypoxia Executive Summary
3. Hypoxia Overview
4. Hypoxia- Analytical Perspective In-depth Commercial Assessment
5. Hypoxia Pipeline Therapeutics
6. Hypoxia Late Stage Products (Phase II/III)
7. Hypoxia Mid Stage Products (Phase II)
8. Hypoxia Early Stage Products (Phase I)
9. Hypoxia Preclinical Stage Products
10. Hypoxia Therapeutics Assessment
11. Hypoxia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hypoxia Key Companies
14. Hypoxia Key Products
15. Hypoxia Unmet Needs
16 . Hypoxia Market Drivers and Barriers
17. Hypoxia Future Perspectives and Conclusion
18. Hypoxia Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Hypoxia Market https://www.delveinsight.com/report-store/hypoxia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hypoxia-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Hypoxia Epidemiology https://www.delveinsight.com/report-store/hypoxia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hypoxia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products
Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypoxia Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Eli Lilly, Biogen, AesRx, Threshold Pharmaceuticals, GlaxoSmithKline, Roche, Reven Pharmaceuticals here
News-ID: 3108713 • Views: …
More Releases from DelveInsight Business Research
DelveInsight Unveils Comprehensive Epidemiology Assessment of Cutaneous Squamous …
DelveInsight, a global leader in healthcare research and analytics, announces the release of its in-depth Cutaneous Squamous Cell Carcinoma (cSCC) Epidemiology Assessment, providing unparalleled insights into the prevalence of cSCC among solid organ transplant recipients across 15 countries, including the United States, key European nations, and select countries in the Asia-Pacific (APAC) region.
The newly released assessment delivers country-specific epidemiological insights aimed at guiding strategic decision-making for pharmaceutical companies, healthcare providers,…
Unlocking Market Potential: DelveInsight's Comprehensive Patent Foramen Ovale (P …
DelveInsight's Market Size & Forecast Assessment Provides Data-Driven Insights for Patient-Centric Market Expansion Strategies
DelveInsight, a leading healthcare market research and consulting firm, has released an in-depth case study highlighting its latest assessment of the Patent Foramen Ovale (PFO) Device Market across the European Union. This strategic market intelligence report provides a holistic understanding of the patient population, device market size, competitor landscape, and reimbursement scenario, equipping medical device companies with…
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market Poised for …
The Chronic Obstructive Pulmonary Disease (COPD) Treatment Devices Market is set for strong expansion, projected to grow at a CAGR of 6.35% from 2025 to 2032, according to recent industry findings. This growth is primarily fueled by the increasing global prevalence of COPD, escalating exposure to tobacco smoke and air pollution, expanding screening programs, and the rapid development of next-generation respiratory devices such as portable nebulizers and smart inhalers.
The global…
CD40 Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, CD40 pipeline constitutes key companies continuously working towards developing CD40 treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"CD40 Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CD40 Market.
The CD40 Pipeline report embraces in-depth commercial and…
More Releases for Hypoxia
Hypoxia Inducible Factor Alpha inhibitor Market Global Rising Demand & Huge Scop …
The global Hypoxia Inducible Factor Alpha Inhibitor market is projected to reach approximately USD 1.12 billion by 2033, growing at a CAGR of 10.3% from 2024 to 2033.
Hypoxia Inducible Factor Alpha inhibitor Market Overview
The Hypoxia Inducible Factor Alpha (HIF-α) Inhibitor market is witnessing rapid growth driven by its critical role in treating cancers and other hypoxia-related diseases. Increasing research on the molecular pathways involving HIF-α has led to the development…
Hypoxia Market | Analysis by Industry Trends, Size, Share, Company Overview, Gro …
The higher A comprehensive understanding of the strategic study of partnerships, acquisitions, mergers, expansions, and investments is provided by the Hypoxia Market Research Report. Businesses can benefit from the market research analysis and data in this study when planning their production, product launches, costs, inventories, purchases, and marketing activities. This object-oriented market research report was created by combining the best talent solutions, industry insight, industry expertise, and the newest techniques and…
Hypoxia Treatment Market Size Share Growth Opportunities and Forecast 2023-2030
Global Hypoxia Treatment Market Surges to US$ 77.6 Million in 2022, Projected to Reach US$ 134.3 Million by 2030 with a 7.2% CAGR
The global hypoxia treatment market demonstrated remarkable growth in 2022, reaching a valuation of US$ 77.6 million. Forecasts for the period from 2023 to 2030 suggest a robust upward trajectory, with an anticipated market value of US$ 134.3 million, reflecting a Compound Annual Growth Rate (CAGR) of 7.2%.
Hypoxia,…
Hypoxia Market Drivers, Industry Threats, and Opportunities By 2028
Data Bridge Market Research analyses that the hypoxia will exhibit a CAGR of around 7.50% for the forecast period of 2021-2028.
A few of the most important objectives of the world class Hypoxia report include; study and forecast the market size in the worldwide market. As well, it defines, explains and forecasts the market by various segments such as type, application, end-use, and region. The report also studies and compares the…
Hypoxia Market is Projected to Grow During the Forecast Period 2022-2032 - Estim …
The Hypoxia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypoxia pipeline products will significantly revolutionize the Hypoxia market dynamics.
DelveInsight's "Hypoxia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypoxia, historical and forecasted epidemiology as well as the Hypoxia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Hypoxia Chamber Market to Register Steady Growth During 2031
Hypoxia Chamber Market: Overview
The hypoxia chamber market has made strides on the back of the growing application of these in cell culture studies. They are utilized in regulating the oxygen levels through control of hypoxia in cell culture in vitro. Over the years, the hypoxia chamber market has seen new avenues from the rise in demand in various animal studies and cell research studies. In recent years, the use of…
